TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26474864
Drug: Inhaled Fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Fluticasone Furoate (FF)
Study: 26474864
Drug: Inhaled Vilanterol
Normalized name: fluticasone / vilanterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Vilanterol (VI)
Study: 26474864
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FF and VI (FF/VI)
Study: 24584918
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg (loading dose)
Study: 18295212
Drug: Misoprostol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (800 microg) administered vaginally
Study: 17301564
Drug: Intermittent antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent antiretroviral therapy (8-week off, 8-week on regimen)
Study: 17301564
Drug: Intermittent antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent antiretroviral therapy
Study: 319117
Drug: Flurbiprofen (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (120 mg daily for six weeks)
Study: 319117
Drug: Ibuprofen (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (2400 mg daily for six weeks)
Study: 31515173
Drug: Patches plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patches plus nicotine e‐cigarette
Study: 31515173
Drug: Patches plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patches plus nicotine‐free e‐cigarette
Study: 31515173
Drug: Patches only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patches only
Study: 28103052
Drug: Micronutrients +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrients + medication
Study: 28103052
Drug: Medication only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only (Control)
Study: 21332679
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with intrathecal morphine
Study: 9163639
Drug: CDP840 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP840 (15 mg b.i.d. for 9.5 days)
Study: 9163639
Drug: CDP840 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP840 (15 and 30 mg single dose)
Study: 30390148
Drug: Feedback Informed
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback Informed Treatment (FIT)
Study: 22155477
Drug: Dopaminergic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic medication ON
Study: 22155477
Drug: No dopaminergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dopaminergic medication OFF
Study: 17215845
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice consumption (concomitantly or 2 hours before fexofenadine administration)
Study: 15164249
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate with E-Lyte supplements (Group 1)
Study: 15164249
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate without E-Lyte supplements (Group 2)
Study: 8777618
Drug: Pentoxifylline (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1.2 g daily, divided into three doses for 2 months)
Study: 6596060
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase therapy (1 million IU over 20 minutes)
Study: 30711868
Drug: Treatment-as-usual (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (n = 27)
Study: 29479906
Drug: Bevacizumab treatment
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab treatment in patients with exudative ARMD and POAG
Study: 29479906
Drug: Bevacizumab treatment
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab treatment in patients with DME and POAG
Study: 16885205
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation therapy
Study: 19258303
Drug: Motivational orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational orientation intervention combined with Parent-Child Interaction Therapy (PCIT)
Study: 11087700
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (high response)
Study: 11087700
Drug: Sulfasalazine treatment
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine treatment (moderate response)
Study: 9305476
Drug: Enema (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enema (100 mL suspension, 1 g mesalazine)
Study: 9305476
Drug: Rectal foam
Normalized name: Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal foam (1 g mesalazine in 5 mL concentrate, expanding to 40 mL on actuation)
Study: 9305476
Drug: Suppository (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository (1 g mesalazine)
Study: 3512970
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (cisdiamminedichloro-platinum plus methotrexate)
Study: 27511847
Drug: TARGIT‐IORT (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TARGIT‐IORT (single-dose intraoperative radiation therapy)
Study: 27511847
Drug: EBRT (external
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT (external beam radiation therapy)
Study: 23284643
Drug: Umeclidinium (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium (500 µg) and vilanterol (50 µg) combination
Study: 23284643
Drug: Umeclidinium (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium (500 µg) alone
Study: 23284643
Drug: Vilanterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilanterol (50 µg) alone
Study: 20192619
Drug: 20% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% lignocaine patch
Study: 18184544
Drug: Sijunzi Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sijunzi Decoction (100 ml) administered via nasogastric tube from the second postoperation day to the 9th postoperation day, along with isocaloric and isonitrogonous enteral diet for 8 days
Study: 18184544
Drug: Isocaloric and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric and isonitrogonous parenteral diet for 9 days
Study: 8136110
Drug: Quinapril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (mean dose 32 mg/24 h)
Study: 8136110
Drug: Captopril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (mean dose 132 mg/24 h)
Study: 2199681
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg twice a day)
Study: 27768831
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg subcutaneous once)
Study: 27768831
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg oral weekly for 6 months)
Study: 23850898
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg misoprostol vaginally at 6 hours before outpatient hysteroscopy and placebo tablets rectally at 60 minutes before the procedure.
Study: 23850898
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac sodium rectally at 60 minutes before the procedure and placebo tablets rectally at 6 hours before outpatient hysteroscopy.
Study: 23850898
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets vaginally at 6 hours before outpatient hysteroscopy and placebo tablets rectally at 45 to 60 minutes before the procedure.
Study: 21788632
Drug: Maximal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal treatment group (mobile and web-based self-management patient coaching system)
Study: 21788632
Drug: Maximal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal treatment group
Study: 21788632
Drug: Maximal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal treatment group and Usual care
Study: 17013438
Drug: 6-methylprednisolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-methylprednisolone (20 mg)
Study: 15287932
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg (one-dose)
Study: 15287932
Drug: Acarbose 300
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 300 mg/day for 8 weeks
Study: 15287932
Drug: Acarbose (one-dose)
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose (one-dose)
Study: 8612858
Drug: Intranasal buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buserelin acetate started in the midluteal phase
Study: 8612858
Drug: Intranasal buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buserelin acetate started in the early follicular phase
Study: 1611136
Drug: ponalrestat (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ponalrestat (600 mg daily)
Study: 6360414
Drug: Cholestyramine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (6 g four times daily)
Study: 16820546
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg twice per day)
Study: 28628768
Drug: Internet delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet delivered Cognitive Behavior Therapy (ICBT) as an add‐on to usual care
Study: 28628768
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) provided at their antenatal clinic
Study: 25740744
Drug: DAG oil
Normalized name: Daglutril
DrugBank: Daglutril (DB05796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAG oil (25 mL/d for 120 days)
Study: 25740744
Drug: TAG oil
Normalized name: ProVent SKIN TAG OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAG oil (25 mL/d for 120 days)
Study: 23465817
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal gel (VG)
Study: 18663631
Drug: Estrogen and
Normalized name: Conjugated estrogen and norgestrel only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen and estrogen/progestin hormone therapies (HT)
Study: 18663631
Drug: Timing hypothesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing hypothesis for hormone therapy
Study: 14689344
Drug: Mupirocin therapy
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin therapy
Study: 14689344
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no therapy
Study: 1793154
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (CPM) and high-dose methotrexate (MTX) with coordinated intrathecal therapy (TIT)
Study: 6342785
Drug: Cyclacillin, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclacillin, administered three times a day for ten days
Study: 6342785
Drug: Amoxicillin, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, administered similarly
Study: 29024579
Drug: Droxidopa 600
Normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droxidopa 600 mg
Study: 29024579
Drug: Droxidopa 2000
Normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droxidopa 2000 mg
Study: 12942493
Drug: Aspirin 150
Normalized name: aspirin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 150 mg per day
Study: 1498266
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg diclofenac hydrogel bead (HGB) capsule after a standardized breakfast
Study: 1498266
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg diclofenac hydrogel bead (HGB) capsule under fasted conditions
Study: 26116561
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) group program
Study: 20051618
Drug: Baseline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline treatment programs (Control)
Study: 11558858
Drug: Losartan monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan monotherapy (50 to 150 mg)
Study: 11558858
Drug: Losartan/HCTZ (50/0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/HCTZ (50/0 to 50/12.5 to 100/25 mg)
Study: 9755543
Drug: salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol 50 mg twice a day
Study: 9755543
Drug: salbutamol 200
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol 200 mg four times a day
Study: 31485804
Drug: Betaine hydrochloride
Normalized name: Betaine Hydrochloride
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine hydrochloride (BHCl) 4500 mg
Study: 23801579
Drug: Teplizumab (14-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teplizumab (14-day full-dose)
Study: 19336502
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg) added to aspirin
Study: 10873076
Drug: Idoxifene 40
Normalized name: Idoxene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idoxifene 40 mg/day for 14-21 days
Study: 8296487
Drug: Thymostimulin treatment
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin treatment (6 subjects)
Study: 3113973
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg X kg‐1 once daily for 3 days
Study: 3113973
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg X kg‐1 thrice daily for one day
Study: 3113973
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg X kg‐1 thrice daily for one day
Study: 29445116
Drug: Traditional ophthalmic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional ophthalmic microscope (TM) during 25-gauge pars plana vitrectomy (PPV)
Study: 20868279
Drug: Full-dose nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose nevirapine (FD)
Study: 20868279
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation (DE) nevirapine
Study: 17119047
Drug: Nurse-administered intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered intervention consisting of cognitive behavioral therapy and medications
Study: 17119047
Drug: Nurse-administered intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered intervention and Usual care
Study: 14624421
Drug: Acetylcysteine 600
Normalized name: acetylcysteine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine 600 mg b.i.d. (five doses)
Study: 7699420
Drug: 'eight‐drugs‐in‐one‐day' chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 'eight‐drugs‐in‐one‐day' chemotherapy regimen
Study: 2954253
Drug: Pirprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirprofen (1200 mg daily)
Study: 2954253
Drug: Pirprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirprofen (800 mg daily)
Study: 2954253
Drug: Naproxen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (1000 mg)
Study: 27697758
Drug: Tafenoquine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine (300 mg) plus dihydroartemisinin-piperaquine (120 mg/960 mg for 36 to <75 kg; 160 mg/1,280 mg for ≥75 to 100 kg)
Study: 27697758
Drug: Tafenoquine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine (300 mg) plus artemether-lumefantrine (80 mg/480 mg)
Study: 24241095
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (oral capsule, 3 g/d)
Study: 21146844
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (liquid diet on postoperative day 2, soft diet from day 3 until discharge)
Study: 10881255
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen (oral Premarin 0.625 mg daily)
Study: 7604069
Drug: Theophylline effervescent
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline effervescent tablet (Euphyllin quick 200)
Study: 25876740
Drug: CR+G (genetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR+G (genetic test results and counseling)
Study: 16912619
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg PO betamethasone
Study: 16912619
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg IM dexamethasone
Study: 8070785
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acids infusion
Study: 8070785
Drug: Intra-amniotic amino
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic amino acids infusion
Study: 31592728
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with anticoagulation alone
Study: 31592728
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for femoral-popliteal DVT
Study: 28624307
Drug: HBVaxPro challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBVaxPro challenge dose
Study: 26241077
Drug: Low-tidal volume
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-tidal volume ventilation (6 ml/kg predicted body weight)
Study: 26241077
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care ventilation (10 ml/kg)
Study: 17493498
Drug: Experimental medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental medications
Study: 19803539
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 IV infusion every 21 days
Study: 19803539
Drug: Pac3w (Paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pac3w (Paclitaxel 175 mg/m2 IV infusion every 21 days)
Study: 19803539
Drug: Pac1w (Paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pac1w (Paclitaxel administered in 1-week cycles)
Study: 10981242
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g every eight hours
Study: 10981242
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g every eight hours
Study: 6419574
Drug: Oral sustained-release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained-release nitroglycerin (SRNG, 6.5 mg)
Study: 30615058
Drug: Higher triglycerides
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher triglycerides (TG) ≥150 mg/dl
Study: 30615058
Drug: Lower total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower total cholesterol (TC) ≥200 mg/dl
Study: 30615058
Drug: Lower low-density
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower low-density lipoprotein cholesterol (LDL-C) ≥130 mg/dl
Study: 21410100
Drug: Functional pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional pain control infusion pump
Study: 21410100
Drug: Placebo pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pain control infusion pump
Study: 15581425
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg b.d. for 7 days or until discharge
Study: 3498392
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg X kg‐1 propofol
Study: 3498392
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg X kg‐1 ketamine
Study: 22780582
Drug: 7.5% CO₂
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% CO₂ inhalation
Study: 9451886
Drug: MIBI bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIBI bone scans post-chemotherapy
Study: 8179134
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg human corticotropin releasing hormone
Study: 8179134
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg human corticotropin releasing hormone
Study: 8179134
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no human corticotropin releasing hormone)
Study: 3332509
Drug: 2 tablets
Normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of 'Fansimef' (500 mg mefloquine base, 1000 mg sulfadoxine, 50 mg pyrimethamine)
Study: 3332509
Drug: 3 tablets
Normalized name: Xpovio 60 MG Weekly Dose Carton Pack, 4 Blister Cards, 3 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets of 'Fansimef' (500 mg mefloquine base, 1000 mg sulfadoxine, 50 mg pyrimethamine)
Study: 21145578
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg dose of 2009 H1N1 vaccine
Study: 21145578
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg dose of 2009 H1N1 vaccine
Study: 21145578
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg dose of 2009 H1N1 vaccine in patients older than 60 years with severe asthma
Study: 21145578
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg dose of 2009 H1N1 vaccine in patients older than 60 years with severe asthma
Study: 21145578
Drug: Both 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 15 μg and 30 μg doses of 2009 H1N1 vaccine
Study: 22802432
Drug: 2009 H1N1
Normalized name: influenza A virus A/California/7/2009 (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2009 H1N1 vaccine